Studio di [177lu] lu-dotatato negli adulti con meningioma intracranico di grado 1-3 intracranico progressivo (MOMENTUM-1)
Momentum-1: uno studio multicentrico, randomizzato, in aperto, di fase II di [177lu] Lu-dotatato negli adulti con meningioma progressivo di grado 1-3 intracranico
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Study participants will be randomized by a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the [177Lu]Lu-DOTATATE alternative treatment arm.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Sylvia C Kurz, MD,PhD
- Numero di telefono: 203-785-5616
- Email: Sylvia.Kurz@yale.edu
Luoghi di studio
-
-
California
-
Irvine, California, Stati Uniti, 92697
- Reclutamento
- University of California, Irvine
-
Investigatore principale:
- Daniela Bota, MD, PhD
-
Contatto:
- Manisha Dandekar
- Email: mdandeka@hs.uci.edu
-
La Jolla, California, Stati Uniti, 92093
- Reclutamento
- University of California San Diego - Moores Cancer Center
-
Investigatore principale:
- Jona Hattangadi-Gluth, MD
-
Contatto:
- Mohammad Amjad
- Email: mtamjad@health.ucsd.edu
-
Los Angeles, California, Stati Uniti, 90033
- Reclutamento
- USC Keck School of Medicine
-
Contatto:
- Christine Duran
- Email: duran_c@med.usc.edu
-
Investigatore principale:
- Aram Modrek, MD, PhD
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Yale University
-
Investigatore principale:
- Sylvia Kurz, MD, PhD
-
Contatto:
- Amy Rodrigues, CCRC
- Numero di telefono: 203-260-9632
- Email: amy.rodrigues@yale.edu
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32207
- Reclutamento
- Baptist MD Anderson Cancer Center
-
Investigatore principale:
- Michael Olson, MD PhD
-
Contatto:
- Email: CTOinterest@bmcjax.com
-
Sub-investigatore:
- Andre Alvarez, MD PhD
-
Miami, Florida, Stati Uniti, 33146
- Reclutamento
- University of Miami
-
Contatto:
- Lily Friedman
- Email: lxf699@med.miami.edu
-
Investigatore principale:
- Marina Kushnirsky, MD
-
Miami, Florida, Stati Uniti, 33176
- Reclutamento
- Baptist Health Medical Group Oncology
-
Investigatore principale:
- Matthew Hall, MD
-
Contatto:
- Nicolas Morales
- Email: nicolas.morales1@baptisthealth.net
-
Tampa, Florida, Stati Uniti, 33543
- Reclutamento
- Moffitt Cancer Center
-
Contatto:
- Abdullah Abdelkawy
- Email: Abdullah.abdelkawy@Moffitt.org
-
Investigatore principale:
- Andre Luiz Beer Furlan, MD, PhD
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30318
- Reclutamento
- Piedmont Healthcare
-
Contatto:
- Jeff Whorton, BSN,RN
- Email: jeff.whorton@piedmont.org
-
Investigatore principale:
- Adam Nowlan, MD, MPH
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Indiana University
-
Investigatore principale:
- Kathryn Nevel, MD
-
Contatto:
- Lauren Perrey-Moore, RN
- Email: lperry@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa Health Care
-
Contatto:
- Kristin West, RN, BSN
- Email: kristin-gaimari-varner@uiowa.edu
-
Investigatore principale:
- Kristin Plichta, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber/Harvard Cancer Center
-
Contatto:
- Kathryn Partridge
- Email: Kathryn_Partridge@DFCI.HARVARD.EDU
-
Investigatore principale:
- Gilbert Youssef, MD
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan Rogel Cancer Center
-
Contatto:
- Jen Thomas
- Email: jennifkt@med.umich.edu
-
Investigatore principale:
- Sean Miller, MD
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Hospital
-
Contatto:
- Jennifer Cooper
- Email: jcoope13@hfhs.org
-
Investigatore principale:
- Tobias Walber, MD, PhD, MPH
-
-
New York
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- NYU Lagone Health
-
Investigatore principale:
- Marissa Barbaro, MD
-
Contatto:
- Olga Garduno-Ortega
- Email: Olga.Garduno-Ortega@nyulagone.org
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 22708
- Reclutamento
- Duke University Medical Center
-
Investigatore principale:
- Margaret Johnson, MD
-
Contatto:
- Kelly Moulton
- Email: kelly.moulton@duke.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Thomas Jefferson University Hospital
-
Investigatore principale:
- Iyad Alnahhas, MD
-
Contatto:
- Oleksandr Kolesnikov
- Numero di telefono: 215-600-9151
- Email: ONCTrialNow@jefferson.edu
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- MD Anderson Cancer Center
-
Contatto:
- Wathoo Chetna
- Email: cwathoo@mdanderson.org
-
Investigatore principale:
- Carlos Kamiya-Matsuoka, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Medical College of Wisconsin
-
Contatto:
- Bailee Fritz
- Email: bfritz@mcw.edu
-
Investigatore principale:
- Michael Straza, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
STEP 1 REGISTRATION
- Aged >= 18 years
- Histologically confirmed diagnosis of WHO grade 1-3 meningioma
- Disease progression following at least one prior surgical intervention (biopsy or resection) and at least one prior course of radiation.
- The patient is not considered a candidate for additional surgery and/or radiation or the patient has declined additional surgery and/or radiation.
- Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
- Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion
- The following scans must be available for submission for central radiology review:
- Pre-progression gadolinium-enhanced MRI brain scan no older than 12 months (379 days) that serves as a reference for evaluation of radiographic disease progression
- Progression gadolinium-enhanced MRI brain scan
STEP 2 REGISTRATION
- Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion.
- [68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
- Both the patient and investigator must agree that the patient will NOT receive SSTR2-targeted therapy, surgical resection, or radiation therapy until progression of disease while on study treatment.
- Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
- Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
- Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):
- Absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin ≥ 8 g/dL
- Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
- AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN)
- Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
- Potassium within normal limits.
Exclusion Criteria:
- Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
- Patients with radiation-associated meningiomas.
- Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column. Meningiomas invading the skull base or orbits are not excluded.
- Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide. No limit on number of prior non-SSTR2-tartgeted systemic therapies.
- Unstable neurological symptoms requiring steroids to control symptoms at a dose of >2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
- Patients requiring immediate local therapy (e.g. surgical resection).
- Surgical procedure within the timeframes listed below, prior to step 2 registration.
- 28 days from any prior craniotomy
- 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
- Treatment within the timeframes specified below, prior to step 2 registration.
- 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
- 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
- A target lesion is excluded if it has received any of the following:
- More than 2 total prior courses of radiation
- More than 1 prior course of standard fractionated external beam radiation therapy (EBRT)
- Radiation treatment to the target lesion completed <24 weeks (168 days) before Step 2 registration.
For purposes of this criterion, one course of EBRT counts as one course regardless of duration, and each course of stereotactic radiation (1-5 fractions) counts as one course. Accordingly, a target lesion may have received at most one prior course of EBRT plus one prior course of stereotactic radiation, or two prior courses of stereotactic radiation. Prior radiation history must be evaluated on a lesion-by-lesion basis, including radiation delivered before any subsequent surgical resection.
- All types of radioligand therapy at any time prior to registration. Radioligands received for diagnostic purposes are not exclusionary.
- Known hypersensitivity to somatostatin analogues or any component of the [68Ga]Ga- DOTATATE or [177Lu]Lu-DOTATATE formulations.
- Active infection requiring current use of intravenous therapy with antibiotics.
- Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
- An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
- Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: [177Lu]Lu-DOTATATE
Study participants receive [177Lu]Lu-DOTATATE |
The treatment regimen consists of 4 (+2 optional) administrations of [177Lu]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
Altri nomi:
|
|
Altro: Control
Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to [177Lu]Lu-DOTATATE at progression |
Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Systemic SOC therapy with one of the following agents: bevacizumab, everolimus, or sunitinib.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression Free Survival (PFS)
Lasso di tempo: Assessed up to 4 years
|
Proportion of patients alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression free survival at 6 months (PFS-6)
Lasso di tempo: 6 months
|
Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria |
6 months
|
|
Overall Survival at 12 months (OS-12)
Lasso di tempo: 12 months
|
Proportion of participants alive at 12 months |
12 months
|
|
Overall survival (OS)
Lasso di tempo: Assessed up to 4 years
|
Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
|
Progression-free Survival after cross-over (PFS2)
Lasso di tempo: Assessed up to 4 years
|
Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first. |
Assessed up to 4 years
|
|
Disease Control Rate (DCR)
Lasso di tempo: Assessed up to 4 years
|
Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria |
Assessed up to 4 years
|
|
Objective response rate (ORR)
Lasso di tempo: Assessed up to 4 years
|
Proportion of patients achieving complete or partial response as per RANO meningioma criteria. |
Assessed up to 4 years
|
|
Number of participants by highest grade treatment-emergent adverse event (TEAE):
Lasso di tempo: Assessed up to 4 years
|
Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event). |
Assessed up to 4 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Sylvia C Kurz, MD, PhD, Yale University
- Investigatore principale: Erik P Sulman, MD,PhD, Duke University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, tessuto nervoso
- Neoplasie del sistema nervoso
- Neoplasie, tessuto vascolare
- Neoplasie meningee
- Neoplasie del sistema nervoso centrale
- Meningioma
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Azoli
- Indoli
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Macrolidi
- Lattoni
- Pirroli
- Sirolimus
- Sunitinib
- Bevacizumab
- Everolimo
- lutetium lu 177 dotato
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- RTOG 3523
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .